Electrophysiology

Freudenberg Medical establishes second production facility in Costa Rica

Retrieved on: 
星期三, 二月 14, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, PV, Medicine, Multimedia, Electrophysiology, CDMO, Freudenberg Group, Environment, Renewable energy

View the full release here: https://www.businesswire.com/news/home/20240214384260/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240214384260/en/
    Freudenberg Medical CEO, Dr. Mark Ostwald, at the groundbreaking ceremony in Costa Rica (Photo: Business Wire)
    “We are proud to be one of the first global CDMO partners in Costa Rica, having established our first production facility here more than 12 years ago,” said Dr. Mark Ostwald, CEO of Freudenberg Medical during the groundbreaking ceremony for the new facility.
  • Within 3 years of opening, a further 50,000 square feet will be added, quadrupling Freudenberg Medical’s total footprint in Costa Rica.
  • During 2025, the existing facility will become Freudenberg Medical's specialized Costa Rica site for primary processing technologies including molding and extrusion of thermoplastics for medical applications while assembly operations will be moved to the new facility.
  • “The investment in this new site underlines Freudenberg Medical’s confidence in Costa Rica as an integral part of our global growth strategy,” said Róger Gómez, VP/General Manager of Freudenberg Medical in Costa Rica.

CytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology Applications

Retrieved on: 
星期一, 二月 5, 2024
Research, General Health, Pharmaceutical, Data Management, Technology, Semiconductor, Science, Biotechnology, Stem Cells, Other Technology, Other Science, Health, Epithelium, Laboratory automation, Cell biology, Electronics, Cell, B cell, Harvard University, Electrophysiology, USD, Exhibition, Data science, Medium (website), Drug discovery, Computer, Pixel, Metabolism, SLAS, Toxicology, Data collection, Television

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.

Key Points: 
  • Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.
  • Pixel delivers simultaneous multi-modal, high-resolution readouts in 96- or 384-well plates, enabling cell monitoring and data collection at unprecedented scale.
  • It’s widely applicable for in vitro cell biology applications including drug discovery, from target validation to toxicology screening.”
    CytoTronics’ early-access program for Pixel Primo empowers cell biologists to unlock applications that were previously inaccessible.
  • The early-access program includes applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

Integer to Showcase Recently Acquired Capabilities and New Technologies at MD&M West 2024

Retrieved on: 
星期四, 二月 1, 2024
Neuromodulation, Electrophysiology, MD, Integer, Patient, Gen, Second generation, Anaheim Convention Center, Risk, Acquisition, Cardio, Arrhythmia, Blood vessel, Medical imaging

PLANO, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leader in medical device outsource manufacturing, will join innovators and industry leaders around the world in exhibiting at MD&M West, Feb. 6-8, 2024, at the Anaheim Convention Center in Anaheim, California.

Key Points: 
  • Integer’s exhibit will spotlight the recent strategic acquisitions of InNeuroCo and Pulse Technologies, each of which have further enhanced Integer’s capability spectrum in the medical device sector.
  • The acquisition of InNeuroCo brings specific expertise in neurovascular solutions and advanced catheter technologies, while the combination with Pulse Technologies enhances capabilities in precision micro machining, backed by proprietary technologies and a focus on high-growth medical markets.
  • Cardio and Vascular Solutions: A full range of electrophysiology, structural heart, and neurovascular product solutions including high-performing guidewires, steerable introducers and sheaths, therapy delivery systems, and implant technologies.
  • In addition to Integer’s exhibit at booth #1439, MD&M West 2024 attendees can also visit Pulse Technologies at booth #2844 to learn more about complex micro machining for critical medical device components.

BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy

Retrieved on: 
星期二, 一月 30, 2024
Physician, Mayo Clinic, Electrophysiology, Workforce, NFT, Software, Cleveland Clinic, PURE, Organization, Medical device

Westport, CT, Jan. 30, 2024 (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced a workforce reduction, intended to reduce annual cash burn by 50%.  The Company is reducing its internal workforce, which is expected to be completed by January 31. The Company is also shifting its business model and seeks to partner with organizations for sales distribution and clinical support of its PURE EP™ Platform.

Key Points: 
  • The Company is reducing its internal workforce, which is expected to be completed by January 31.
  • The Company is also shifting its business model and seeks to partner with organizations for sales distribution and clinical support of its PURE EP™ Platform.
  • "BioSig is at an important juncture, and we are taking steps to streamline our corporate structure.
  • Their hard work and dedication were integral to bringing the PURE EP™ Platform to where it is today," said Ken Londoner, Chairman and CEO of BioSig.

St. Joseph's Children's Hospital First in Tampa Bay to Implant Leadless Pacemaker in Pediatric Heart Patient

Retrieved on: 
星期五, 二月 2, 2024
Partnership, Medicine, Ventricular septal defect, Leg, Life, Hospital, Child, Medtronic, Electrophysiology, Heart, Patient, Nissan Micra, Skin, Congenital heart block, Dizziness, Blood, Infection, Medical device

TAMPA, Fla., Feb. 2, 2024 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital recently implanted its first leadless pacemaker, the first among all Tampa Bay hospitals to leverage this advanced technology in a pediatric patient.

Key Points: 
  • TAMPA, Fla., Feb. 2, 2024 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital recently implanted its first leadless pacemaker, the first among all Tampa Bay hospitals to leverage this advanced technology in a pediatric patient.
  • The procedure was performed by Dr. Kelvin Lau, director of pediatric electrophysiology at St. Joseph's Children's Hospital, on a teenage girl who was born with isolated congenital heart block.
  • The Patel Children's Heart Institute at St. Joseph's Children's Hospital is home to the Tampa Bay area's only comprehensive congenital heart disease program.
  • A partnership between St. Joseph's Children's Hospital and UPMC Children's Hospital of Pittsburgh provides families across Florida with unprecedented access to the highest level of pediatric heart care available.

CathVision to Showcase ECGenius System and AI Algorithms at AF Symposium 2024

Retrieved on: 
星期二, 一月 30, 2024
Signal, EP, Workflow, PVI, AI, University, Electrophysiology, Noise, Extended play, Acquisition, Algorithm

COPENHAGEN, Denmark, Jan. 30, 2024 /PRNewswire/ -- CathVision today announced the ECGenius™ System will be featured in a Spotlight Session led by Dr. Larry Chinitz at the 29th Annual International AF Symposium in Boston, February 1-3, and highlighted at the CathVision booth (#419).1

Key Points: 
  • He will detail his experiences with CathVisions's advanced EP recording system, discussing how the acquisition of high-fidelity, low-noise cardiac electrograms create the necessary foundation to implement intelligent, automated analyses provided by the CARDIALYTICS™ AI algorithms.
  • "AI in the EP Lab: Replacing Legacy EP Recording Standards with ECGenius and AI-Algorithms to Effectively Measure Success of Ablation Outcomes"
    Reinforcing the benefits of the ECGenius System, two poster presentations will also be shared during the AF Symposium featuring data from studies conducted at the University of Vermont.
  • ECGenius System and our CARDIALYTICS AI algorithms deliver the quality and streamlined processes to capture, assess, and ablate confidently."
  • For more information about ECGenius System and CARDIALYTICS, or to meet with CathVision at the AF Symposium, please contact us and connect on LinkedIn .

Endologix Announces that Art Taylor Joins Board of Directors

Retrieved on: 
星期四, 一月 25, 2024
General Health, Health, Cardiology, Medical Devices, Electrophysiology, Vascular disease, Neurology, Ophthalmology, Knowledge, Spine, AAA, Abdominal aortic aneurysm, Management

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Art Taylor has been appointed to the Endologix Board of Directors.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Art Taylor has been appointed to the Endologix Board of Directors.
  • Art Taylor has over 30 years of experience in operational and financial executive leadership within the medical device, pharmaceutical, and high-tech industries.
  • Mr. Taylor served as a member of the Board of Directors for several medical device firms that were subsequently acquired and is currently a Board member for three early stage companies, and Providence Medical Technology, a commercial stage company.
  • "We are excited to welcome Art Taylor to the Endologix Board of Directors," expressed Matt Thompson, MD, President, and CEO of Endologix.

First Coast Cardiovascular Institute and CardioHealth Partner to Advance Cardiovascular Care for Northeast Florida Residents

Retrieved on: 
星期一, 一月 29, 2024
Electrophysiology, Valvular heart disease, Patient, Cardiology, Hypertension, Trust, Health, Partnership, Atrial fibrillation, History, Echocardiography, FACC, FCCI, Amputation, Heart, Cardiovascular disease

JACKSONVILLE, Fla., Jan. 29, 2024 /PRNewswire-PRWeb/ -- First Coast Cardiovascular Institute, a Cardiovascular Logistics partner practice that offers cardiovascular medicine, sleep medicine, pulmonology, and amputation prevention to residents in Northeast Florida and Southern Georgia, has joined forces with CardioHealth, a Jacksonville-based cardiovascular practice that specializes in delivering exceptional care to patients with hypertension, congestive heart failure, atrial fibrillation, and valvular heart disease. Together, they aim to advance cardiovascular care across Northeast Florida.

Key Points: 
  • Together, they aim to advance cardiovascular care across Northeast Florida.
  • "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI.
  • "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI.
  • "This collaboration between First Coast Cardiovascular Institute and CardioHealth marks a significant milestone for both practices," said David Konur, CEO of Cardiovascular Logistics.

PrepMD's Online Cardiac Healthcare Training Solutions Now Approved for CEUs

Retrieved on: 
星期五, 一月 26, 2024
Online, Electrophysiology, Knowledge, ASRT, Accreditation, Nursing, 3D, EP, Malcolm Gladwell

BRAINTREE, Mass., Jan. 26, 2024 /PRNewswire/ -- PrepMD, the leading cardiac healthcare solutions provider, announced today the accreditation of their online healthcare training programs for Nursing Continuing Education Units (CEUs).

Key Points: 
  • BRAINTREE, Mass., Jan. 26, 2024 /PRNewswire/ -- PrepMD, the leading cardiac healthcare solutions provider, announced today the accreditation of their online healthcare training programs for Nursing Continuing Education Units (CEUs).
  • PrepMD's comprehensive online training solutions have long been recognized for their excellence in upskilling clinical staff in device clinics, EP Labs, and Cath Labs.
  • At PrepMD, we are committed to delivering the highest quality remote monitoring, staffing, and training solutions for cardiac healthcare providers.
  • With PrepMD's Online Training Programs now approved for Nursing CEUs, individuals can advance their knowledge and maintain their professional credentials conveniently and effectively.

Integer Holdings Corporation Announces Preliminary Unaudited Sales Results and Acquisition of Pulse Technologies

Retrieved on: 
星期三, 一月 10, 2024
Electrophysiology, Patient, NPV, Central Time, Adjustment, GAAP, Acquisition, Conference, Medtech, Depreciation, Engineering, Integer, Growth

PLANO, Texas, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced fourth quarter 2023 preliminary unaudited sales are expected to be in the range of $411 million to $413 million, an increase of 10% to 11% compared to fourth quarter 2022. Preliminary unaudited full year 2023 sales are expected to be in the range of $1.595 billion to $1.597 billion, an increase of 16% compared to full year 2022.

Key Points: 
  • Based in Quakertown, Pennsylvania, Pulse Technologies also provides proprietary advanced technologies, including Hierarchical Surface Restructuring (HSR™), Scratch-Free Surface Finishes, and Titanium Nitride Coatings.
  • “The acquisition of Pulse Technologies is directly aligned with Integer’s strategy to expand our capabilities and capacity in targeted growth markets,” said Payman Khales, Integer President, Cardio & Vascular.
  • “We were immediately impressed with Pulse Technologies’ long-standing customer relationships, technical talent, unique technologies, shared values, and capacity for growth.
  • Pulse Technologies’ estimated full year 2023 sales are approximately $42 million with 2023 adjusted EBITDA(a) expected to be approximately $11 million.